Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Newsoara BioPharma Expands Global Rights to vTv’s PDE4 Inhibitor HPP737 in $135 Million Deal

Fineline Cube Feb 11, 2026
Company Deals Medical Device

Siemens Healthineers Partners with Northwestern Medicine to Advance Precision Cancer Care

Fineline Cube Feb 11, 2026
Company Deals

Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III

Fineline Cube Feb 11, 2026
Company Deals

uBriGene Biosciences Partners with Innovec Biotherapeutics on AAV Gene Therapy for Hereditary Eye Diseases

Fineline Cube Feb 11, 2026
Company Deals

China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million

Fineline Cube Feb 11, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

SciClone’s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer

Fineline Cube Feb 11, 2026
Company Drug

Hengrui Pharma’s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication

Fineline Cube Feb 11, 2026
Company Drug

Shanghai Pharmaceuticals Gets NMPA Approval for Phase I Clinical Study of B019 CAR-T Cell Injection

Fineline Cube Nov 3, 2023

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading pharmaceutical distribution company in China, has...

Company Drug

I-Mab and HI-Bio’s Felzartamab Earns Breakthrough Therapy Designation from US FDA

Fineline Cube Nov 3, 2023

China-based I-Mab (NASDAQ: IMAB) and its US partner HI-Bio have announced that they have received...

Company

Eli Lilly & Co. Reports 36% YOY Sales Growth in Q3 2023 with Key Drug Performances

Fineline Cube Nov 3, 2023

Eli Lilly & Co., (NYSE: LLY) has announced its financial results for the third quarter...

Company

Organon Reports Q3 2023 Financials with Mixed Results, Notable Decline in Women’s Health Sales

Fineline Cube Nov 3, 2023

US-based Organon (NYSE: OGN) has released its financial results for the third quarter of 2023,...

Company Drug

Pfizer Inc. Reports Q3 2023 Revenue Contraction and Launches Cost Realignment Program

Fineline Cube Nov 2, 2023

US pharmaceutical giant Pfizer Inc., (NYSE: PFE) has released its financial results for the third...

Company Deals

AstraZeneca Partners with Cellectis for Next-Generation Cell and Gene Therapies

Fineline Cube Nov 2, 2023

UK pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has announced a strategic partnership with Cellectis (EPA:...

Company

Daiichi Sankyo Reports 19.5% YOY Revenue Growth in First Half of Fiscal 2023

Fineline Cube Nov 2, 2023

Japan’s Daiichi Sankyo (TYO: 4568) reported a robust 19.5% year-on-year (YOY) increase in revenue for...

Company Drug

EpimAh Biotherapeutics to Present First-in-Human Results for EMB-06 at SITC Annual Meeting

Fineline Cube Nov 2, 2023

Shanghai-based biotechnology company EpimAb Biotherapeutics has announced that it will present first-in-human results for its...

Company

GSK Reports Modest 2% YOY Growth in Q3 2023 Finances, Vaccines Unit Soars 24%

Fineline Cube Nov 2, 2023

UK-based pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK) has released its financial report for the third...

Company Deals

We-Linking Secures Angel Financing for Implantable Brain Computer Interface Development

Fineline Cube Nov 2, 2023

Shenzhen-based company We-Linking, a specialist in implantable brain computer interfaces (BCI), has reportedly raised tens...

Company Drug

Chongqing Precision Biotechnology’s PCAR-19B Receives CDE Nod for Breakthrough Therapy Designation

Fineline Cube Nov 2, 2023

The China’s Center for Drug Evaluation (CDE) website has indicated that Chongqing Precision Biotechnology Co.,...

Company

Astellas Pharma Inc. Reports Moderate Revenue Growth in H1 Fiscal 2023 Financials

Fineline Cube Nov 2, 2023

Japan-based Astellas Pharma Inc., (TYO: 4503) has released its financial results for the first half...

Company Drug

Sichuan Kelun-Biotech’s SKB264 Receives Priority Review Status for TNBC Treatment in China

Fineline Cube Nov 2, 2023

The China’s Center for Drug Evaluation (CDE) website has indicated that Sichuan Kelun-Biotech Biopharmaceutical Co.,...

Company Drug

Hinova Pharmaceuticals’ HP518 Receives NMPA Approval for mCRPC Clinical Trial

Fineline Cube Nov 2, 2023

China-based biopharmaceutical company Hinova Pharmaceuticals (SHA: 688302) has announced that it has received clinical trial...

Company Drug

Sino Biopharmaceutical’s TQG3902 Injection Receives NMPA Approval for Septic Shock Clinical Trial

Fineline Cube Nov 2, 2023

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biotech company based in China, has announced that...

Company Drug

Sirnaomics’ STP705 Demonstrates Positive Results in Phase I Focal Fat Reduction Study

Fineline Cube Nov 2, 2023

Sirnaomics Ltd (HKG: 2257) has announced positive safety and efficacy results from a Phase I...

Company Deals

3SBio Inc. and CStone Pharmaceuticals Enter Strategic Partnership for Nofazinlimab

Fineline Cube Nov 2, 2023

China-based 3SBio Inc., (HKG: 1530) has announced a strategic partnership and exclusive licensing agreement with...

Company Deals

Resolian Expands Global Reach with Acquisition of China-Based Denali Medpharma

Fineline Cube Nov 2, 2023

US-based bioanalytical contract research organization (CRO) Resolian has announced the acquisition of China-based CRO Denali...

Company Drug

Hainan Poly Pharm Receives FDA Approval for PL002 in Primary Liver Cancer Surgery

Fineline Cube Nov 1, 2023

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced that it has received clinical...

Company Drug

Changchun BCHT Biotechnology Receives NMPA Approval for Anti-Tetanus Monoclonal Antibody Injection

Fineline Cube Nov 1, 2023

China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced that it has received clinical...

Posts pagination

1 … 407 408 409 … 623

Recent updates

  • Newsoara BioPharma Expands Global Rights to vTv’s PDE4 Inhibitor HPP737 in $135 Million Deal
  • Siemens Healthineers Partners with Northwestern Medicine to Advance Precision Cancer Care
  • SciClone’s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer
  • Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III
  • Hengrui Pharma’s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Newsoara BioPharma Expands Global Rights to vTv’s PDE4 Inhibitor HPP737 in $135 Million Deal

Company Deals Medical Device

Siemens Healthineers Partners with Northwestern Medicine to Advance Precision Cancer Care

Company Drug

SciClone’s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer

Company Deals

Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.